News

It's the time of year when optical chain executives take time to review their company's performance and revise the strategic plan.

This has been a year filled with many exciting developments in cataract surgery.

Marketing the right accessories and getting a little creative with displays is a sure way to boost profit in your office.

The Jakarta, Indonesia, ophthalmic lens manufacturing plant of Vision-Ease Lens (VEL) sustained damage from a major fire in November.

NeoVista Inc.'s new epimacular brachytherapy system (Vidion Anti-Neovascular Surgical System) for the treatment of age-related macular degeneration is now available in the United Kingdom

In an effort to increase patient adherence to therapy and safety, as well as to maximize effectiveness, two eye-health products (Macular Health Formula and Dry Eye Formula, EyeScience) are sold to both eye-care professionals for resale from their offices and through a mass market retailer.

Manus C. Kraff, MD, of Chicago is the 2009 recipient of the American Medical Association (AMA) Benjamin Rush Award for Citizenship and Community Service.

OD-OS has received FDA 510(k) clearance and CE mark approval for its recently released navigated retina laser therapy system (Navilas).

The FDA has reopened a public docket to receive information and comments about LASIK devices, it was reported in the Nov. 13 Federal Register. The agency will accept remarks until Nov. 15, 2010.

An investigational telescope implant has been given an 8-0 approvable vote by the FDA advisory panel.

As attendees gather for the Wilmer Eye Institute's 22nd annual Current Concepts in Ophthalmology meeting, they can expect the agenda to focus on clinical use and medical issues important to ophthalmology.

The retail optical industry is down 2.5% in 2009, according to industry published data.

If you don't know the question you want to ask, you can't ask the question to get the information you need to stay out of trouble.

When performing cataract surgery, it is critical to understand the properties of ophthalmic and viscosurgical devices.

A key role of ARVO in the eye and vision research community is to recognize excellence.

To a busy ophthalmologist, time is a valuable commodity, and with proposed Mediare cuts looming, it is a daily focus and concern.

A phacoemulsification software upgrade further enhances safety, efficiency, and control for surgeons performing torsional ultrasound with proprietary handpiece and phaco system.

An intraoperative wavefront aberrometer seems to be highly beneficial for patients and surgeons because it allows the surgeon to manage astigmatism effectively.

Combination therapy of an anti-platelet-derived growth factor aptamer plus an anti-vascular endothelial lesion regression in 91% of eyes with choroidal neovascularization compared with only 16% of eyes with anti-VEGF monotherapy.

A newly upgraded spectral-domain, optical coherence tomography (OCT) device with a non-mydriatic, color fundus camera enables clinicians to detect retinal abnormalities often missed during routine patient exams.

Making phone calls to remind patients about upcoming appointments may become a thing of the past.

There has been a new development in the way Current Procedural Terminology (CPT) Category III codes, also known as T-codes, are viewed, reimbursed, and treated in the means of medical billing and coding.

My friends in practice tell me that the starting pay packages being offered to ophthalmologists right out of training are becoming more modest.

Visual performance is degraded by several optical phenomena including wavefront aberrations, light scattering, and diffraction.

Ophthalmic surgical instrument manufacturers and distributors work in a constantly evolving and increasingly global marketplace, and in late 2009, are meeting challenges posed by new procedures and changing government regulations.

Although heuristic factors will always be a part of the art of ophthalmomology, we are now in an era in which payments for medical treatments are going to be increasingly scrutinized for therapeutic effectiveness.

The Centers for Medicare and Medicaid Services (CMS) reversed a reimbursement decision that would have forced clinicians to switch treatment for patients with wet age-related macular degeneration from bevacizumab to ranibizumab.

Carl Zeiss Meditec introduced its new suite of treatment workflow and data management systems at the annual meeting of the American Academy of Ophthalmology.